Premium
Role of cyclic GMP in the modulation by endothelium of the adrenolytic action of prazosin in the rat isolated aorta
Author(s) -
Alosachie Iyad,
Godfraind Théophile
Publication year - 1986
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1986.tb11152.x
Subject(s) - prazosin , antagonist , endothelium , medicine , antagonism , endocrinology , competitive antagonist , chemistry , agonist , cyclic guanosine monophosphate , guanosine , pharmacology , receptor , biology , biochemistry , nitric oxide
1 The effect of endothelium on the adrenolytic action of prazosin was studied in the rat isolated aorta. 2 Prazosin showed a non‐competitive type of antagonism in preparations with intact endothelium while in preparations where endothelium had been removed, prazosin at concentrations between 0.3 nM‐10 nM acted as a competitive antagonist. 3 Methylene blue, used to decrease tissue levels of guanosine 3′: 5′‐cyclic monophosphate (cyclic GMP), converted prazosin from a non‐competitive antagonist into an apparently competitive antagonist in the presence of endothelium. 4 Increasing tissue levels of cyclic GMP by incubation with 8‐bromo‐cyclic GMP converted prazosin from an apparently competitive antagonist into a non‐competitive antagonist in the absence of endothelium. 5 Analysis of concentration‐response curves for noradrenaline in the presence and absence of endothelium showed that the affinity for noradrenaline was the same but the efficacy, measured by estimating the receptor reserve, was not; it was lower in the presence than in the absence of endothelium. 6 It was concluded that the change in the mode of antagonism of prazosin after endothelium removal could be related to an alteration in the efficacy of the agonist, brought about by a change in the tissue levels of cyclic GMP.